SYnAbs S.A. products

When you perform intraperitoneal injection of hapten or highly homologous antigens in mouse species, most of the time your project is going to fail. Due to poor immunogenic properties and low molecular weight, your antigen is going to be eliminated in animal urine without generating any humoral immune response. That`s why we`ve created SynAbs in the first place, based upon an exclusive asset: the rat-LOU species and rat-LOU IR983 myeloma cell line, developed in 1983 by Hervé Bazin in Catholique University of Louvain-la-Neuve (UCL).